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ABSTRACT
A significant impending threat to the public health system is the rise of multidrug
resistant bacteria. An attractive potential option to combat this is antimicrobial peptides
(AMPs). AMPs are peptide chains with lengths that range from 10 to 70 amino acid
residues that show antimicrobial activity. AMPs tend to have less toxicity than other
antibiotic therapies, have a broader range of activity, and have a decreased resistance
development by the target cells. Short AMPs are especially attractive due to their stability
as well as their ability to penetrate cell membranes. With a wide range of possible AMPs
available, further characterization of these molecules is needed before using AMPs in a
clinical setting. For this study, 4 previously identified AMPs (WLRRIKAWLRR [RR],
WLRRIKAWLRRIKA [RIKA], IIGGR [IGR], and HPQYNQR [HQ]) were synthesized
using solid phase peptide synthesis and evaluated for antimicrobial activity. Previous
studies regarding MIC assay methods indicate that special considerations, such as test
vessel material and growth media, are required for AMPs to obtain accurate MIC data.
Therefore, a resazurin colorimetric assay was conducted in a 96-well polypropylene
microtiter plate with iso-sensitest broth. Eight species were challenged with these 4
peptides, many for the first time. Peptides RR and RIKA demonstrated antimicrobial
activity in 6 and 7 species, respectively. RIKA consistently demonstrated more
antimicrobial activity than RR. IGR and HQ showed no antibiotic activity in this study.
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This novel study involved synthesizing four AMPs, designing a novel
experimental method for antibiotic activity of AMPs, and expanding antimicrobial
activity testing to eight bacterial species to allow for a comprehensive comparison of
these potential novel antibiotic therapies. This comparison could renew interest in these
AMPs and possible combination therapies.
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CHAPTER 1
INTRODUCTION

1.1

Discovery and Development of Antibiotics

Since their discovery, antibiotics have become the widespread clinical standard
therapy for illnesses caused by bacteria. In 2015, the number of antibiotics consumed
worldwide was estimated to be 42 billion defined daily doses and that number is
projected to increase 200% by 2030.1 Arsphenamine was first synthesized in 1907 by
Paul Ehrlich and released as the first antibiotic in 1910 as a new treatment for syphilis.
This discovery led Ehrlich to develop the concept of a “magic bullet”, a drug that kills
specific microbes without harming the body. The magic bullet concept led Ehrlich and
other scientists to search for compounds with specificity for individual microbes. A few
years later, the discovery of penicillin from Penicillium rubens in 1928 sparked the
golden age of discovery of natural bacterial products that demonstrated antibacterial
activity that continued through the 1940s and 1960s (Figure 1-1).2 The antibiotics
developed during this era of discovery served as precursors for the antibiotics commonly
used today.3

1

2

Figure 1-1. Timeline indicating the years antibiotics were approved as well as
relevant developments.4
During the golden age of discovery, novel antibiotics were sorted into 23 different
classes of antibiotics.2 These classes were defined by the structure of the antibiotic as
well as its target in bacterial cells and are still used today to define new drugs. Antibiotic
targets include inhibition of cell wall synthesis, protein synthesis, DNA/RNA synthesis,
folate synthesis, and membrane disruption (Figure 1-2). The first commercially available
antibiotic class was sulfonamide, which disrupts folate synthesis.4 One of the most known
and used antibiotic classes are beta lactams, which contain a four-membered beta lactam
ring. Beta lactams target cell wall synthesis and are effective against both Gram-positive
and Gram-negative bacteria, also referred to as having a broad spectrum of activity.2
Tetracyclines and macrolides are also considered broad spectrum antibiotics, as they
target protein synthesis in both Gram-positive and Gram-negative bacteria. Quinolones
and fluoroquinolones disrupt DNA synthesis and primarily target Gram-positive
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bacteria.4 Polymyxins consist of five polypeptides that target Gram-negative bacteria by
disrupting the cell membrane. The last novel classes of antibiotics in clinical use were
discovered in the 1980s.5 Any developments since the 1980s are modifications of
previously known antibiotics, known as the golden age of medicinal chemistry. This span
of decades consists of modifications of previously discovered antibiotic compounds and
the optimization of antibiotic therapies, including the introduction of combinational
therapeutic approaches. Though the golden age of medicinal chemistry prolonged the
effective usage of current antibiotics, there is a definitive need for the discovery of novel
antibiotic agents.

Figure 1-2. Classes of antibiotic targets in Gram-positive and Gram-negative cells.6
When considering antibiotic advancement and use, one must also consider the
antibiotic pipeline. The antibiotic pipeline refers to all the potential antibiotic therapies in
various stages of development before going into clinical use.4,5 During the golden age of
discovery, the antibiotic pipeline was numerous in every stage of development.

4
Following the development of the antibiotic oxazolidinones in 1987, a drop-off in
discovery occurred.7 The cause of this slowdown was the large number of antibiotics
available for treatment as well as the significant costs of putting a new therapy through
the required safety testing.3,4 This lull in the discovery of new antibiotics drastically
decreased the number of antibiotics in the pipeline (Figure 1-3). Generally, a multitude
of therapies are in the initial discovery and preclinical stages of the development pipeline,
which involves testing for antimicrobial activity as well as toxicity to eukaryotic cells.
After extensive testing in this stage, the therapies that continue to show promise will
move to animal testing followed by clinical testing. The late stages of preclinical studies
and the initial clinical studies cause many of the therapies to be abandoned due to
inactivity, toxicity, or side effects. Today, the number of antibiotics in the pipeline is a
fraction of that in the early years of discovery.6 This is cause for concern due to the recent
rise in antibiotic resistant bacterial infections.

Figure 1-3. Antibiotic Therapy pipeline. Adapted from “Drugs for bad bugs:
confronting the challenges of antibacterial discovery” using Biorender.com8
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1.2

Rise of Antibiotic Resistance

The concept of the magic bullet gives rise to the question whether or not one
magic bullet drug could be used for multiple microorganisms. Each antibiotic targets
different cell types as well as different parts of the cell. When evaluating antibiotics, one
must consider the spectrum of activity and the mechanism of action. An antibiotic’s
spectrum of activity is referring to the diversity of its targeted bacteria, which is directly
related to the antibiotic’s specific target within the bacteria.6 There are five classes of
antibiotic targets: inhibition of cell wall synthesis, membrane disruption, inhibition of
protein synthesis, inhibition of folate synthesis, and inhibitions of DNA or RNA synthesis
(Figure 1-2).4 Disruption of cell wall synthesis can cause changes in osmotic pressure,
initiating cell lysis. Cell membrane disruption includes the leakage of ions and small
molecules, depriving cells of nutrients and disrupting homeostasis.6,7 Inhibition of protein
synthesis can cause disruption in cell growth, division, and metabolic processes.4,6 The
disruption of DNA and RNA synthesis interferes with protein production as well as cell
replication.4 The disruption of folate synthesis prevents the conversion of uracil to
thiamine, which prevents DNA biosynthesis.4 Different bacteria types can have
predisposed, or intrinsic, resistance to antibiotics due to the inability of the antibiotic to
reach its target (Figure 1-4).3 For example, Gram-negative bacteria have a thinner
peptidoglycan cell wall, but also an outer cell membrane. For many antibiotics that target
inside the cell or the cell wall, Gram-negative bacteria are intrinsically resistant due to the
impermeability of the outer cell membrane. Because of intrinsic resistance, developing a
large library of antibiotics with varying targets is essential and so a more appropriate
allocation of resources than trying to develop one antibiotic that can target all bacteria.

6

Figure 1-4. Mechanisms of Antibiotic Resistance.2
With the use of antibiotics, came the rise of acquired antibiotic resistance.
Acquired antibiotic resistance involves bacteria that were once susceptible to a drug
acquiring the ability to continue to grow and reproduce despite the presence of
antibiotics. This occurs through genetic changes such as mutation, transformation,
transduction, or conjugation. The mechanisms of resistance include modification or
destruction of the antibiotic, the development of efflux pumps that decrease drug uptake,
and modification of the antimicrobial target (Figure 1-4).4,5 Acquired antibiotic
resistance can vary greatly in complexity and occur through various biochemical
pathways, which makes accounting for this type of resistance difficult. Rather than
developing entirely new antibiotic classes, medicinal chemistry focused on developing
combinational therapies to account for acquired resistance, such as beta-lactamase
inhibitors.4 In response to the introduction of beta-lactams, bacteria were able to show
resistance to this antibiotic class by releasing beta-lactamase, which broke open the active
site of beta-lactam drugs.9 The antibiotic activity of beta-lactams was revived when betalactamase inhibitors were taken in addition to the beta-lactam antibiotic. Though this
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approach worked for beta-lactam antibiotics, it does not work for all antibiotics. Acquired
resistance mechanisms, such as the overexpression of efflux pumps, still pose a
significant threat to antibiotic therapies.
Though antibiotic resistance occurs naturally, certain behaviors and practices can
promote the rapid growth of the antibiotic resistance crisis. Social actions that are
unfavorable for bacteria can increase the rate at which resistance develops, as this adds
selective pressure for mutation. Using antibacterial soaps and sanitizers too frequently
selects for resistance by killing off the bacteria that cannot withstand the chemicals but
the bacteria that happen to have a mutation, such as the presence of membrane efflux
pumps, survive and are able to reproduce.3,5 Increased use of antibiotics also provides
repeated exposure, which selects for the development of resistance. Recent studies have
also suggested that the use of antibiotics that are commonly used in winter months, such
as penicillin and macrolides, can cause increases in resistance in a wide range of
antibiotic classes.10 This indicates that the overuse of one antibiotic can have lasting
effects on the overall antibiotic resistance crisis. After the golden age of discovery for
antibiotics, the antibiotic use in healthcare as well as agriculture soared with limited
regulation.11 Here, antibiotics are often used in sub-therapeutic levels in animals to
promote growth and prevent disease. These practices have shown to increase the
resistome, which refers to the collection of all antibiotic resistance genes among
bacteria.12 Though there is a critical need for novel antibiotics, there is also a great need
to decrease behaviors that favor the rapid growth of the antibiotic resistome.
The use of antibiotics brought about the rise of acquired antibiotic resistance in
pathogenic bacteria. The first recorded instance of antibiotic resistance was a bacterial
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infection that was resistant to penicillin in 1942.10 Antibiotic resistance among clinically
relevant bacterial strains is an impending threat to public health. A group of clinically
concerning pathogens with high virulence and incidence of antibiotic resistance are
known as the ESKAPE pathogens, which include Enterococcus facium, Staphylococcus
aureus, Klebsiella pneumoniae, Acintobacter baumannii, Pseudomonas aeruginosa,
Enterobacter aerogenes, and Escherichia coli.4 Bacterial infections that were once easily
treatable are now unresponsive to some of the strongest antibiotics on the market, like S.
aureus and Mycobacterium tuberculosis.2,6 The introduction of antibiotics to the clinical
setting provided life-saving care to millions of people for many years, though widespread
use led to the novel challenge of antibiotic resistance. The number of multidrug resident
bacteria has continued to increase and the World Health Organization (WHO) declared
the condition of the antibiotic resistance crisis as “dire”.13 Multidrug resistant pathogens,
such as MRSA as well as multidrug-resistant tuberculosis, are now a large concern in
healthcare settings and are especially difficult to treat.14
1.3

Peptides with Antimicrobial Activity

Antimicrobial peptides (AMPs) first became of interest in the 1980s, after several
AMPs were isolated from insects and mammalian neutrophil granules.2,4 Though the
characteristics of AMPs can vary, many AMPs with significant antimicrobial activity
tend to have similarities. Having a cationic charge is one of the most common
characteristics of AMPs, as the positive charge attracts to the negatively charged cell
membrane of bacteria.6 Though residues lengths tend to range from 10 to 70 residues,
shorter AMPs have added stability as well as increased ability to enter the cell
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membrane.4,6 Concerns for all potentially therapeutic AMPs include having high
cytotoxicity for human cells and maintaining stability in physiological conditions.
The mechanism of action for most AMPs are poorly understood, which makes
predicting the mechanism of action for novel AMPs difficult. AMPs with strong cationic
properties tend to be involved in cell membrane disruption in one of three proposed
models: barrel-stave, toroidal pore, and carpet bomb (Figure 1-5). Barrel-stave and
toroidal pore models involved AMPs with cationic and anionic sections that allow for the
attraction and integration into the cell membrane, forming pores.6,15 The model for cell
membrane disruption is named the “carpet bomb” model and involves the extensive
coverage of the cell membrane by the AMPs, causing the membrane to destabilize. 4,15 It
is important to continue research on the mechanisms of actions of AMPs in order to gain
a more comprehensive understanding of the potentially novel antibiotic therapies.

Figure 1-5. Common mechanisms of AMPs. A) Toroidal pore model. B) Barrel-stave
model. C) Carpet Bomb model.15
The focus of this research project was on the viability and activity of four
previously identified AMPs (Table 1-1). Peptides WLRRIKAWLRR (RR) and
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WLRRIKAWLRRIKA (RIKA) were suspected to destabilize the cell membrane as their
primary mechanism of action.16 Other antibiotic mechanisms focus on inhibiting critical
cellular processes. Replication is prevented by inhibitions of nucleic acid biosynthesis as
well as inhibition of cell division. Cellular maintenance pathways, such as protein
biosynthesis and protease activity, can also be targeted by AMPs.15 The mechanisms of
action for peptides IIGGR (IGR) and HPQYNQR (HQ) are still unknown, though both
AMPs are derived from human leukocyte cathepsin G protein.17 Previous research has
shown antimicrobial activity in a number of oral bacteria, such as Acintomyces viscous
and Streptococcus sanguis.17 This suggests that they likely have similar activity, which is
inhibition of protease activity.12,17 Further study is needed in order to pinpoint the exact
mechanism of action of IGR and HQ.
Table 1-1. AMPs Synthesized in this Project
Name Sequence
Ref. Strains Previously Tested
IGR

IIGGR

17

HQ

HPQYNQR

17

RR

WLRRIKAWLRR

18

RIKA WLRRIKAWLRRIKA

18

Nissicca gonorhoaeae,
Acintobacter acintomycomitans,
Escherichia coli,
Staphylococcus aureus
Nissicca gonorhoaeae,
Acintobacter acintomycomitans,
Escherichia coli,
Staphylococcus aureus
Staphylococcus aureus,
Staphylococcus epidermidis,
Pseudomonas aeruginosa
Staphylococcus aureus,
Staphylococcus epidermidis,
Pseudomonas aeruginosa

Concentration
500 μg/mL

500 μg/mL

424.96 μg/mL
498.2 μg/mL

Previous research has established that peptides RR and RIKA have antimicrobial
activity against S. aureus and Staphylococcus epidermidis.16,18 However, there have not
been extensive studies on the antimicrobial activity of a wide range of bacteria, especially

11
Gram-negative bacteria. In comparison, the antimicrobial activity of the peptides IGR
and HQ were primarily focused on Gram-negative bacteria, while lacking data regarding
Gram-positive bacteria.17 This research expands our knowledge in that it tested the
spectrum of activity of these four AMPs to each other by achieving two objectives. The
first objective involved synthesis and confirmation of IGR, HQ, RR, and RIKA by Solid
Phase Peptide Synthesis. The second objective involved measuring the antibiotic activity
of each peptide with a range of bacterial strains as well as comparing the four AMPs to
each other. The bacteria included in this project are known to be clinically relevant, liable
to antibiotic resistance, and provide Gram reaction variability. This project provides more
insight on the spectrum of activity of these AMPs.

CHAPTER 2
MATERIALS AND METHODS

2.1
2.1.1

Materials

Peptide Synthesis
Solid phase peptide synthesis was conducted in a 50 mL Glass Solid Phase

Peptide Synthesis Vessel (Catalog Number: CG-1866-12, Chemglass) using a Rink
Amide resin (Fmoc-Rink Amide AM Resin, 0.61 mmol/g, Catalog Number: RRZ001,
AAPPTec). Regents used for synthesis include Dimethylformamide (N,NDimethylformamide, Sequencing Grade, Catalog Number: BP1160-4, Fisher
BioReagents), Piperidine (Hexahydropyridine, ≥99.5%, Catalog Number: 411027-1L,
Sigma-Aldrich), Dichloromethane (Dichloromethane, ≥99.5%, Catalog Number:
BDH1113-4LG, VWR), Isopropanol (2-Propanol, Certified ACS, Catalog Number:
A416P-4, Fisher Scientific), 1-hydroxybenzotriazole monohydrate (HOBt, Catalog
Number: CXZ010, PPTTec), O-Benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluoro-phosphate (HBTU, Catalog Number: CXZ020, PPTTec), N,NDiisopropylethylamine (DIPEA, ≥99%, Catalog Number: D125806-500ML, Sigma
Aldrich), Triisopropylsilane (TIPS, 98%, Catalog Number: 233781, Sigma, Aldrich), 1,2Ethanedithiol (EDT, 98+%, Catalog Number: L12865, Alfa Aesar), Trifluoroacetic acid
(TFA, 99%, Catalog Number: T6508, Sigma Aldrich), and Ethyl Ether anhydrous
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(Diethyl ether, BHT stabilized/certified ACS, Catalog: E138-1, Fisher Scientific).
Laboratory equipment used for peptide synthesis included a Rotary evaporator (Digital
Rotary Evaporator, Catalog Number: RE301, Yamato Scientific America), a Centrifuge
(Benchtop General Purpose Centrifuge, Catalog Number: 10830-746, VWR), and a
Freeze Dryer (FreeZone 2.5 Liter -50C Benchtop Freeze Dryer, Catalog Number:
700202000, Labconco). Amino acids were purchased from PPTTec (Appendix 6-1).
2.1.2

Analysis of Antimicrobial Activity
Mueller Hinton II agar was used for overnight cultures (Catalog Number: 211438,

Fisher Scientific). Iso-sensitest broth was inoculated from overnight plate cultures and
3.3x iso-sensitest broth was used for 96-well MIC assay (Catalog Number: CM0473B,
ThermoFisher Scientific). Normal saline (0.9%) was made with sodium chloride (ACS,
Catalog Number: MSX0420-1, Fisher Scientific) and water. Samples were compared
with a 0.5 McFarland Latex Standard (Catalog Number ML05, Hardy Diagnostics)
visually and with a spectrophotometer (Thermo Spectronic 4001, ThermoFisher
Scientific). AlamarBlue was used as the colorimetric indicator (BUF012A, BioRad). MIC
assays were conducted in polypropylene 96-well plates (Catalog Number 3879, Corning
Inc. through VWR).
2.2

Peptide Synthesis

The first objective of this project is synthesizing the four AMPs. This was
completed with a Rink Amide resin and Fluorenylmethyloxycarbonyl (Fmoc) protecting
group (Figure 2-1) via stepwise Solid Phase Peptide Synthesis (SPPS).19 This method
involves attaching an initial Fmoc-protected amino acid to the Rink Amide resin,
removing the Fmoc protecting group, and adding additional Fmoc-protected amino acids
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until the desired peptide is complete. SPPS was chosen because synthesis performed on a
solid support allows for the isolation of the product after each amino acid addition
without using extraction, recrystallization, or chromatography and increases the synthesis
yield.

Figure 2-1. Fmoc-Rink Amide Resin. Fmoc protecting group (Red). Rink Amide Linker
(Orange). Resin (Purple). Created using ChemDraw.

2.2.1

Column Preparation and Deprotection Step
Preparation for SPPS required adding 300 mg of Rink Amide Resin to into a glass

50 mL SPPS vessel with 4-5 mL dimethylformamide (DMF) and N2 gas for 30 minutes.
The DMF was then drained. Next, 5 mL of 20% Piperidine in DMF was added with N 2
for 30 minutes, this is the initial reaction involving the removal of Fmoc from the Rink
Amide linker by piperidine to give a reactive amine, also known as a deprotection step
(Figure 2-2). Deprotection is the initial step of SPPS and is repeated before the addition
of each amino acid.

15

Figure 2-2. Mechanism for the Deprotection Step of the Fmoc-Rink Amide Resin to
initiate Solid Phase Peptide Synthesis with 20% Piperidine. Fmoc (Red). Rink Amide
Linker (Orange). Resin (Purple). Piperidine (Blue). Created using ChemDraw.

2.2.2

SPPS Washing Cycle
A series of four steps is used following the deprotection to wash the resin prior to

the addition of an amino acid. Each step is a specified number of washes with 5-6 mL of
solution with N2. The first step uses DMF and includes a 5-minute incubation with the
resin prior to draining (repeated for a total of 3 rinses). The second step uses DCM and
includes a 3-minute incubation with the resin prior to draining (repeated for a total of 2
rinses). The third step uses isopropyl and incudes 3-minute incubation with the resin prior
to draining. The final step uses DMF and includes a 5-minute incubation with the resin
prior to draining (repeated for a total of 3 rinses).
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2.2.3

Coupling Reaction: Amino Acid Addition
Next, a Fmoc-protected amino acid is added to the Rink Amide linker by a

carbonyl substitution reaction, also known as a coupling reaction (Figure 2-3). The
coupling reaction requires a mixture of coupling reagents including 0.07 g of 1hydroxybenzotriazole monohydrate (HOBt), 0.1735 g of hexafluorophosphate
benzotriazole tetramethyl uranium (HBTU), and the amino acid in enough
dimethylformamide (DMF) to dissolve the mixture (Table 6-1 for amount of each amino
acid added). This mixture was then added to the resin in the column with N 2 and finally,
160 μL of N,N-Diisopropylethylamine (DIPEA) was added. DIPEA and DMF function to
maximize solvation and minimize hydrogen bonding while HOBt and HBTU function to
activate the amino acid being added to the growing peptide chain. The amino acid
addition order is the reverse compared to amino acid addition in physiological conditions,
meaning peptides are synthesized from the C-terminus to N-terminus. A cycle consisting
of deprotection, washing, coupling, and washing was repeated until all amino acids were
chain-linked to the Rink Amide resin.

17

Figure 2-3. Coupling Reaction to Form a Peptide Chain. (A) Deprotonation of protected
amino acid by DIPEA with DMF solvent. (B) Activation of protected amino acid with
HBTU followed by HOBt. (C) Substitution reaction with deprotected peptide chain
attached to Rink Amid resin. Fmoc (Red), resin (Purple sphere), R group of protected
amino acid being added (Pink), Side chain protecting groups (Green circles). Created using
ChemDraw.
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2.2.4

Cleavage from Resin
The synthesized peptide was cleaved from the resin using a mixture containing

0.5 mL TIPS, 0.5. mL water, and 18.5 mL TFA (cleavage cocktail). TFA is a strong
organic acid that separates the Rink Amide linker from the peptide. EDT and TIPS act as
scavengers by quenching the cations formed during deprotection and coupling steps,
preventing extraneous reactions such as the acid-catalyzed oxidation of tryptophan
residues.
Once the last amino acid for the AMP was added (including a deprotection and
wash cycle), 10 ml of the cleavage cocktail was added to the column with N 2 for 30
minutes. (Figure 2-4). N2 was then turned off and the column removed from the flask to
a sterile, pre-weighed 50 mL conical tube. Using a rubber suction ball to apply pressure
to the column and filter the cleaved peptides into the 50 mL conical tube. The column
was returned to the flask. The remaining 10 mL cleavage cocktail was added with N 2 for
10 minutes. N2 was then turned off and the column removed from the flask to the same
50 mL conical tube. Using a rubber suction ball to apply pressure to the column and filter
the cleaved peptides into the 50 mL conical tube. At this point the peptide is in a dilute
suspension but removed from the resin.
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Figure 2-4. Cleavage of Newly formed Peptide with TFA, TIPS, and EDT in H2O.
Peptide (Green), Rink Amide Linker (Orange), Resin (Purple). Created using ChemDraw.
Next, 6 mL of the peptide mixture was transfer to a sterile, pre-weighed 15 mL
conical tube and TFA was evaporated off using rotary evaporation (72°C). TFA was
removed by rotary evaporation and cold diethyl ether was used for the precipitation of the
AMPs. Once evaporation has stopped, the remaining mixture was transferred to a new
sterile, pre-weighed 50 mL conical tube and placed on ice for 10 minutes. Next, diethyl
ether was added to the conical tube to 25 mL and mixed by vortexing. The crude peptide
precipitates were isolated by centrifugation (4500 rpm, 4°C, 5 minutes), with the
supernatant poured off and additional peptide/diethyl ether mixture was added and
centrifuged until only crude peptide was left. The peptide was then suspended in 25 mL
water and frozen overnight in -40°C. The peptides were then freeze-dried for 2-3 days
and then stored at -20°C for long term storage.
To confirm the sequence and purity of the AMPs, the samples were sent to LSU
mass spectrometry facility and confirmed by MALDI. Once confirmed, stock solutions
were made at a final concentration of 1024 μg/mL. For each peptide, 0.01024 g
suspended in 10 mL water, and distributed into 1 mL aliquots creating a stock solution of

20
1024 μg/mL. Aliquots were frozen in water and the remaining dry AMPs were stored at
-20°C.
2.3

Analysis of Antimicrobial Activity

The second objective of this project is accessing the antimicrobial activity of the
synthesized peptides, which will be determined by observing the minimum inhibitory
concentrations (MICs) of each peptide using 8 bacteria (Table 2-1). MICs were
determined using the colorimetric Resazurin microdilution assay in a 96-well format.
AlamarBlue is a cell viability assay reagent that contains the indicator dye, resazurin
(BioRad BUF012A).20 Isolated colonies were collected from fresh cultures on MuellerHinton agar and then transferred to 100 mL iso-sensitest broth (Thermo Scientific
CM0471B). After overnight incubation at 35°C with 6% carbon dioxide, the culture was
spun down (25 mL at a time, 4000 rpm, 4°C, 5 minutes each), resuspended in a total of
20 mL normal saline (0.9% NaCl), adjusted turbidity to a 0.5 McFarland standard using
normal saline, and then further adjusted the suspension to an Optical Density at 550nm
(OD550) of 0.09 to achieve a colony forming unit concentration near the 0.5 McFarland
standard equivalent of 1.5 x 108 cfu/mL of E. coli. The suspension was then diluted 1:20
in normal saline, which roughly equates to 5 x106 cfu/mL E. coli.
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Table 2-1. Bacterial Strains Used in this Project
Strain
Strain Characteristics

Grama

BSLb

Source

Bacillus anthracis
Bacillus cereus
Escherichia coli
Klebsiella pneumoniae
Proteus mirabilis
Pseudomonas aeruginosa
Staphylococcus aureus
Staphylococcus epidermidis

+
+
+
+

2
2
1
2
2
2
2
1

Lab collection
Lab collection
VWR
VWR
VWR
VWR
Lab collection
VWR

a

Sterne
569
ATCC 25992, Serotype O6
ATCC 13882, Serotype 3
NCIMB 13283, Wildtype
ATCC 10145, Schroeter
ATCC 6538, Rosenbach
NCIMB 8853, Wildtype

Gram: Gram reaction
BSL: Biosafety Level

b

To begin the preparation of 75 μL reaction in a 96-well polypropylene plate, 37.5
μL water was added to columns 2 through 9, then 75 μL of 1024 μg/mL peptide in water
was added to column 1 (Figure 6-2). Using a multichannel pipettor, 37.5 μL was taken
from column to column 2, mixed, and then 37.5 μL from column 2 was transferred to
column 3. This continued through column 9, where the final 37.5 μL of peptide and water
was discarded. Next, 22.5 μL 3.3x iso-sensitest broth, 7.5 μL AlamarBlue, and 7.5 μL
bacterial suspension were added to each well. The final bacterial concentration per well
was approximately 5x105 cfu/mL. The peptide concentrations ranged from 512 μg/mL in
column 1 to 2 μg/mL in column 9 in a two-fold serial dilution. Column 10 served as a
positive control, containing the same components as test wells, only with water and no
peptide. Column 11 served as a negative control, containing peptides, but no bacteria.
Column 12, rows A-F served as antibiotic controls. Antibiotic concentrations were
chosen based on preliminary MIC assays (data not shown). Well 12G contained bacteria,
but no drug or peptide. Well 12H contained no drug, peptide, or bacteria. Resazurin
microdilution assays were conducted in triplicate and the MIC will be interpreted as the
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lowest peptide concentration that inhibits bacterial growth after 24-hour incubation.
Growth inhibition is indicated by the well remaining blue and growth is indicated by the
well turning pink. The MICs were observed and demonstrated the differences in
antimicrobial activity.

CHAPTER 3
RESULTS

3.1

Peptide Synthesis

The first objective of this study was to synthesize the four AMPs. Solid phase
peptide synthesis (SPSS) was used to synthesize four previously identified, but not well
characterized, AMPs with suspected antimicrobial properties: IGR, HQ, RR, and RIKA.
SPPS was chosen because synthesis performed on a solid support allows for the isolation
of the product after each amino acid addition without using extraction, recrystallization,
or chromatography and increases the synthesis yield. The cycle of deprotection, washing
coupling, and washing again allowed for the addition of each amino acid with limited
extraneous products. MALDI analysis by Louisiana State University confirmed the
successful synthesis of all four peptides (Appendix 6-3).
3.2

Antimicrobial Activity Analysis

One classic methodology to characterize and compare antimicrobial activities of
antibiotics is to perform minimum inhibitory concentrations (MICs) studies. I chose to
conduct MIC analysis of the 4 AMPs ranging in concentrations from 512 μg/ml to 2
μg/ml on eight bacterial strains. To determine the MICs for the AMPs, AlamarBlue was
used as a qualitative indicator of bacterial cell viability.20 Resazurin is an oxidationreduction indicator that undergoes a colorimetric change in response to cellular metabolic
reduction
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(Figure 3-1). Bacterial cells that survive will reduce resazurin, which colors the solution
pink. The MICs for the Resazurin assays were determined by observation of break from
pink to blue in adjacent wells, with the AMP concentration of the blue wells listed in the
table below as the MIC (Table 3-1). For each bacteria strain, assays were conducted in
triplicate from the same overnight culture and were consistent across all three tests with
the exception for one MIC for RIKA against E. coli.

Figure 3-1. Reduction of Resazurin (Blue) to Resorufin (Pink) to Dihydroresorufin
(Colorless).21

Table 3-1. Minimum Inhibitory Concentration of Synthesized AMPs
MIC (μg/mL)
Strain

Gram

IGR

HQ

RR

RIKA

B. anthracis
B. cereus
E. coli
K. pneumoniae
P. mirabilis
P. aeruginosa
S. aureus
S. epidermidis

+
+
+
+

>512
>512
>512
>512
>512
>512
>512
>512b

>512
>512
>512
>512
>512
>512
>512
>512b

16
32
64
>512
>512
128
128
16c

8
16
32a
512
>512
128
64
8c

Two out of three tests showed the MIC for RIKA against E. coli as 32 μg/mL. One showed 64 μg/mL.
MIC tests for IGR and HQ against S. epidermidis showed purple wells, indicating nearing the MIC at 512
μg/mL.
c
Two out of three tests showed the MIC for RR and RIKA at 16 μg/mL and 8 μg/mL, respectively. One test
showed the MICs one two-fold dilution higher.
a

b

RR and RIKA consistently showed antimicrobial activity for both Gram-positive
and Gram-negative bacteria, including B. anthracis (Figure 3-2), B. cereus (Figure 3-3),
E. coli (Figure 3-4), K. pneumoniae (Figure 3-5, RIKA only), P. aeruginosa (Figure 3-
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7), S. aureus (Figure 3-8), and S. epidermidis (Figure 3-9). For B. anthracis as well as S.
epidermidis, RIKA showed the lowest MIC with 8 μg/mL, followed by RR at 16 μg/mL.
For B. cereus, RIKA had the lowest MIC with 16 μg/mL and RR with 16 μg/mL. The
lowest MIC for E. coli was RIKA at 32 μg/mL, followed by RR with 64 μg/mL. For K.
pneumoniae, RIKA had lowest MIC at 512 μg/mL and not inhibition for any other
peptide. For P. mirabilis, the MICs for RR and RIKA were above 512 μg/mL (Figure 36). For S. aureus, the MIC with RIKA was 64 μg/mL and RR was 128 μg/mL. One MIC
test for RIKA against S. aureus at 4 μg/mL showed no growth and this is likely due to
pipetting error resulting in no bacteria in that well. For P. aeruginosa, both RIKA and RR
showed 128 μg/mL for the MIC. RIKA showed more antibiotic activity over RR. In all
but one bacterial species, P. aeruginosa, the MIC was one two-fold dilution higher for
RR.
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Figure 3-2. MIC assay for Bacillus anthracis.
Rows A and E: IGR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no peptide.
Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Rows B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in
column 9. B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512
μg/mL HQ and no bacteria. Rows C and G: RR starting at 512 μg/mL in column 1
descending in a two-fold dilution to 2 μg/mL in column 9. Wells C10 and G10 contained
bacteria and no peptide. C11 and G11 contained 512 μg/mL RR and no bacteria. Rows D
and H: RIKA starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2
μg/mL in column 9. Wells D10 and H10 contained bacteria and no peptide. Wells D11
and H11 contained 512 μg/mL RIKA and no bacteria. Column 12: A12 contained 4
μg/mL erythromycin descending in a two- fold dilution to 0.125 μg/mL in well F12. G12
contained bacteria and no drug. H12 contained no drug or bacteria.
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Figure 3-3. MIC assay for Bacillus cereus.
Rows A and E: IGR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no peptide.
Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Rows B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in
column 9. B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512
μg/mL HQ and no bacteria. Rows C and G: RR starting at 512 μg/mL in column 1
descending in a two-fold dilution to 2 μg/mL in column 9. Wells C10 and G10 contained
bacteria and no peptide. C11 and G11 contained 512 μg/mL RR and no bacteria. Rows D
and H: RIKA starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2
μg/mL in column 9. Wells D10 and H10 contained bacteria and no peptide. Wells D11
and H11 contained 512 μg/mL RIKA and no bacteria. Column 12: A12 contained 2
μg/mL erythromycin descending in a two-fold dilution to 0.0625 μg/mL in well F12.
G12 contained bacteria and no drug. H12 contained no drug or bacteria.
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Figure 3-4. MIC assay for Escherichia coli.
Rows A and E: IGR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no peptide.
Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Rows B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in
column 9. B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512
μg/mL HQ and no bacteria. Rows C and G: RR starting at 512 μg/mL in column 1
descending in a two-fold dilution to 2 μg/mL in column 9. Wells C10 and G10 contained
bacteria and no peptide. C11 and G11 contained 512 μg/mL RR and no bacteria. Rows D
and H: RIKA starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2
μg/mL in column 9. Wells D10 and H10 contained bacteria and no peptide. Wells D11
and H11 contained 512 μg/mL RIKA and no bacteria. Column 12: A12 contained 64
μg/mL carbenicillin descending in a two-fold dilution to 2 μg/mL in well F12. G12
contained bacteria and no drug. H12 contained no drug or bacteria.
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Figure 3-5. MIC assay for Klebsiella pneumoniae.
Rows A and E: IGR starting at 512 μg/mL in column 1 descending in a twofold dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no
peptide. Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Rows B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in column 9.
B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512 μg/mL HQ and no
bacteria. Rows C and G: RR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells C10 and G10 contained bacteria and no peptide. C11
and G11 contained 512 μg/mL RR and no bacteria. Rows D and H: RIKA starting at 512
μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in column 9. Wells D10 and
H10 contained bacteria and no peptide. Wells D11 and H11 contained 512 μg/mL RIKA and
no bacteria. Column 12: A12 contained 8 μg/mL chloramphenicol descending in a two-fold
dilution to 0.25 μg/mL in well F12. G12 contained bacteria and no drug. H12 contained no
drug or bacteria.
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Figure 3-6. MIC assay for Proteus mirabilis.
Rows A and E: IGR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no peptide.
Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Rows B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in
column 9. B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512
μg/mL HQ and no bacteria. Rows C and G: RR starting at 512 μg/mL in column 1
descending in a two-fold dilution to 2 μg/mL in column 9. Wells C10 and G10 contained
bacteria and no peptide. C11 and G11 contained 512 μg/mL RR and no bacteria. Rows D
and H: RIKA starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2
μg/mL in column 9. Wells D10 and H10 contained bacteria and no peptide. Wells D11
and H11 contained 512 μg/mL RIKA and no bacteria. Column 12: A12 contained 256
μg/mL chloramphenicol descending in a two-fold dilution to 8 μg/mL in well F12. G12
contained bacteria and no drug. H12 contained no drug or bacteria.
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Figure 3-7. MIC assay for Pseudomonas aeruginosa.
Rows A and E: IGR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no peptide.
Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Rows B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in
column 9. B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512
μg/mL HQ and no bacteria. Rows C and G: RR starting at 512 μg/mL in column 1
descending in a two-fold dilution to 2 μg/mL in column 9. Wells C10 and G10 contained
bacteria and no peptide. C11 and G11 contained 512 μg/mL RR and no bacteria. Rows D
and H: RIKA starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2
μg/mL in column 9. Wells D10 and H10 contained bacteria and no peptide. Wells D11
and H11 contained 512 μg/mL RIKA and no bacteria. Column 12: A12 contained 256
μg/mL carbenicillin descending in a two-fold dilution to 8 μg/mL in well F12. G12
contained bacteria and no drug. H12 contained no drug or bacteria.
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Figure 3-8. MIC assay for Staphylococcus aureus.
Rows A and E: IGR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no peptide.
Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Rows B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in
column 9. B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512
μg/mL HQ and no bacteria. Rows C and G: RR starting at 512 μg/mL in column 1
descending in a two-fold dilution to 2 μg/mL in column 9. Wells C10 and G10 contained
bacteria and no peptide. C11 and G11 contained 512 μg/mL RR and no bacteria. Rows D
and H: RIKA starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2
μg/mL in column 9. Wells D10 and H10 contained bacteria and no peptide. Wells D11
and H11 contained 512 μg/mL RIKA and no bacteria. D8 showed no growth and is likely
a pipetting error (Top). Column 12: A12 contained 1 μg/mL erythromycin descending in
a two-fold dilution to 0.03125 μg/mL in well F12. G12 contained bacteria and no drug.
H12 contained no drug or bacteria.
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Figure 3-9. MIC assay for Staphylococcus epidermidis.
Row A and E: IGR starting at 512 μg/mL in column 1 descending in a two-fold
dilution to 2 μg/mL in column 9. Wells A10 and E10 contained bacteria and no peptide.
Wells A11 and E11 contained IGR at 512 μg/mL and no bacteria. Row B and F: HQ
starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2 μg/mL in
column 9. B10 and F10 contained bacteria and no peptide. B11 and F11 contained 512
μg/mL HQ and no bacteria. Row C and G: RR starting at 512 μg/mL in column 1
descending in a two-fold dilution to 2 μg/mL in column 9. Wells C10 and G10 contained
bacteria and no peptide. C11 and G11 contained 512 μg/mL RR and no bacteria. Row D
and H: RIKA starting at 512 μg/mL in column 1 descending in a two-fold dilution to 2
μg/mL in column 9. Wells D10 and H10 contained bacteria and no peptide. Wells D11
and H11 contained 512 μg/mL RIKA and no bacteria. Column 12: A12 contained 0.25
μg/mL erythromycin descending in a two- fold dilution to 0.008 μg/mL in well F12. G12
contained bacteria and no drug. H12 contained no drug or bacteria.
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IGR and HQ showed no antibiotic activity with the bacteria tested in this study.
The MICs for IGR and HQ were not determined and are above 512 μg/mL. The only
notable result is a purple color showing for S. epidermidis at 256 μg/mL IGR and 512
μg/mL IGR (Figure 3-9, Top plate, Wells A1 and E1). The purple color might indicate
some residual AlamarBlue is not being converted and therefore some antimicrobial
activity (see Discussion). This suggests that the MIC for S. epidermidis with IGR and HQ
are possibly between 512 and 1024 μg/mL.

CHAPTER 4
DISCUSSION

4.1

Peptide Synthesis

The MALDI confirmed that my synthesis produced AMPs of the correct mass,
indicating correct sequence and high purity.

4.2

Novel Experimental Design for determining AMP MICs

Upon reviewing the literature on MIC protocols, I learned there is no one “gold
standard” for determining MICs. This stems from the various growth requirements of
pathogens (some fastidious), the absorption of AMPs (positively charged) by the test
vessel (negatively charged), and the definitive identification of the MIC breakpoint.
Keeping these issues in mind, I looked at several standard protocols and came up with my
own experimental design.
A traditional MIC uses Mueller-Hinton broth, a two-fold dilution series of an
antibiotic, a polystyrene 96-well microtiter plate, and a bacterial inoculum equivalent to
5x105 cfu/mL as the final concentration per well.22 Two possible issues with this test
method are the media and the test vessel. Mueller-Hinton can serve as a suitable growth
medium for fastidious pathogens, if properly supplemented.22 If not supplemented, the
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MIC would be inaccurate due to insufficient growth and results would be unreliable. An
alternative growth media used in antibiotic testing is iso-sensitest broth.20 The use of the
iso-sensitest broth enables P. aeruginosa and S. aureus to grow without requiring
supplementation, as would be the case with Mueller-Hinton broth. Considering eight
organisms were tested in this study, using a universal growth medium simplified testing.
Iso-sensitest broth acts as a more universal growth medium while maintaining
comparable MIC results.20 Therefore, iso-sensitest broth was selected for this project.
Most MICs call for a polystyrene 96-well plate, which does not account for the
characteristics of AMPs used in this study. In many cases, this would be suitable.
However, previous studies of MIC assays involving AMPs found that the standard
polystyrene 96-well plates decreased the observed antimicrobial activity.22 The strong
negative charge of polystyrene causes the positively charged AMPs to stick to the sides
of the wells rather than remain in solution. Because of the positive charges on the AMPs,
adjustments must be made to standard MIC assay protocols to obtain more accurate
antimicrobial activity data. The recommendation is to use a polypropylene 96-well plate,
which does not carry a negative charge to eliminate this potential inconsistency with
polystyrene.22 Therefore, I chose to use polypropylene 96-well plates.
Though polypropylene plates took away the concern of the plate charge
interacting with the AMPs, the opaque appearance of polypropylene plates increases the
difficulty of interpreting growth in individual wells. The standard method to determine
growth in a MIC assay in a 96-well plate includes looking for turbidity and sediments at
the bottom of the wells between 16 and 24 hours, something that increases in difficulty
with an opaque test vessel.22 One work around is to use a resazurin colorimetric indicator,
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like AlamarBlue. AlamarBlue is a cell viability indicator that turns pink from blue via a
reduction-oxidation reaction when living cells are present. This allows for a clear color
distinction between wells that contain living bacteria and wells that do not after 24
hours.20 Therefore, I chose to use AlamarBlue as a colorimetric indicator in the MIC
assays and 24-hour incubation periods.
There are extraneous colors, such as purple, light pink, and orange.19 Purple
reactions suggest some reduction of resazurin to resorufin and some unreacted resazurin.
This can be explained by the peptide concentration nearing the MIC or that the peptide
can have bacteriostatic activity, with the peptide limiting metabolic activity. Determining
bacteriostatic activity would require conducting minimum bactericidal concentrations
assays after conducting MIC assays. For light pink wells suggest that some of the
resorufin has been further reduced to dihydroresorufin, which is colorless, but the pH is
still above 4.20,24 Bacteria cultures with extensive growth will appear light pink to clear
because of the additional reduction reactions. Orange wells are indicative of a pH below
3.8. Organisms in orange wells likely either have surface properties or extracellular
secretions that cause a pH drop in the well.
The goal of this experimental design is to provide MIC data that uses standard
methods, while accounting for the special considerations of AMPs. Concentrations, size
of inoculum, and antibiotic controls were used in similar fashions of accepted MIC
standards. The uses of a colorimetric indicator, polypropylene 96-well plates, and isosensitest broth were included to account for the charges of AMPs and to minimize growth
interpretation errors.
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4.3

Antimicrobial Activity of RR and RIKA

Previous studies on RR and RIKA demonstrated antimicrobial activity in 3
pathogens, both Gram-positive and Gram-negative bacteria. This study expands the
number of bacterial organisms tested to 8 to better define the spectrum of activity of these
two AMPs (Table 4-1). The inclusion of novel organisms: B. anthracis, B. cereus, E.
coli, K. pneumoniae, and P. mirabilis suggest a broader spectrum of activity for RR and
RIKA than previously thought. RR and RIKA demonstrated MICs of 64 μg/mL and
lower against B. anthracis, B. cereus, and E. coli, suggesting these AMPs might be
developed into novel therapeutics. Though the MICs of P. mirabilis were not determined
in this study, a foundation for further study was established and possible modifications of
the AMPs can be explored to target this organism.
Table 4-1. AMPs and Previously Tested Bacterial Strains
Previously Tested
Strain

RR

RIKA

IGR

HQ

•

•

•

•

B. anthracis
B. cereus
E. coli
K. pneumoniae
P. mirabilis
P. aeruginosa
S. aureus
S. epidermidis

•
•
•

•
•
•

Previously published data regarding RIKA demonstrated antimicrobial activity
against S. aureus, S. epidermidis, and P. aeruginosa. For S. aureus, published MICs for
RIKA ranged from 3.7 μg/ml (2 μM) to 7.5 μg/ml (4 μM). In contrast, this study
determined the MIC was 64 μg/ml. For S. epidermidis, the previously published MIC for
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RIKA was 3.7 μg/mL (2 μM). In this study, the MIC was 8 μg/mL. For P. aeruginosa,
the previously published MIC for RIKA was 15.1 μg/mL (8 μM) and the MIC in this
study was 128 μg/mL. Data published regarding RR showed antimicrobial activity
typically one concentration higher in the two-fold serial dilution series among these
bacteria. For S. aureus, the previously published MIC for RR was 24.8 μg/mL (16 μM)
and 128 μg/mL in this study. For S. epidermidis, the previous MIC for RR was 12.4
μg/mL (8 μM) and 16 μg/mL in this study. For P. aeruginosa, the previous MIC for RR
was 198.4 μg/mL (128 μM) and was 128 μg/mL in this study. Overall, the MICs
measured in this study were markedly higher than previously published data except for S.
epidermidis with RR and P. aeruginosa with RIKA.
RIKA consistently demonstrates a lower MIC than RR. The only difference
between these two AMPs is the addition of isoleucine, lysine, and alanine to the RR
sequence suggesting that the combination of isoleucine, lysine, and alanine provide
additional antibiotic activity. The combination of cationic amino acids (lysine) and
hydrophobic (isoleucine) amino acids follow the characteristics of AMPs that show a
barrel-stave or toroidal pore mechanism of action.23 This disruption of the cell membrane
causes leakage and eventual cell death. Further study is needed to confirm the mechanism
of action for these AMPs.
The discrepancies in MICs between the two studies are notable but could be
attributed to differences in methods. Previous publications used 16 over 24-hour
incubation periods and it is unclear if the Mueller-Hinton was supplemented, both of
which could cause inaccurate MICs due to reduced overall growth. They also depended
on turbidity to detect growth instead of color. One of the benefits to using resazurin as an
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indicator of growth is its high Kreft’s dichromaticity index, meaning the color change
breakpoint is easy to interpret thereby minimizing human error.24 Given the limited
amount of peptide available, I could not compare the two methods experimentally to see
if these variables are the cause.
4.4

Antimicrobial Activity of IGR and HQ

Previous publications on IGR and HQ determined bactericidal activity (MBC) at
500 μg/mL for both AMPs against E. coli and S. aureus.17 MBCs are typically higher
than MICs, but given the unique methodology used in the previous study and that they
did not report a MIC, no comparison can be made. This study showed no antibiotic
activity (MIC) at 512 μg/ml with one exception. S. epidermidis with IGR at 512 μg/mL
consistently showed a purple color, which suggests some delay in growth possibly due to
it approaching the MIC.
One explanation for the lack of antibiotic activity of these two AMPs with the 8
strains tested could be attributed to the distribution of charged amino acids in the AMPs.
The mechanisms of action of AMPs are still poorly understood, but a slightly positive
charge is thought to be important for the attraction to the negatively charged cell
membrane of bacteria. IGR (IIGGR) is made up of isoleucine, glycine, and arginine.
Isoleucine has a hydrophobic side chain and is uncharged. The side chain for glycine is
only a hydrogen atom, which likely does not add to any antibiotic activity. Arginine has a
positive charge and would likely aid in the attraction to the cell membrane, though only a
weak contribution due to the large number of isoleucine and glycine amino acids.
Previously published data for IGR suggested the terminal arginine is significant to its
antimicrobial activity.17 With HQ (HPQYNQR), there are more positively charged amino
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acids within the peptide (histidine and arginine). Although when one considers the
remaining amino acids, which are hydrophobic, this peptide has a weak positive charge.
AMPs are typically defined as peptides with antimicrobial activity that range from
10 to 70 amino acids.4,15 Considering IGR is only 5 amino acids in length and HQ is 7
amino acids in length, perhaps higher concentrations are needed for significant antibiotic
activity. Both IGR and HQ are domains isolated from cathepsin G, a protein in humans
and mammals that eliminates intracellular pathogens. IGR has previously been shown to
increase antimicrobial activity when used in combination with other longer
AMPs. Future combination studies with both AMPs could provide some novel
therapeutics.

CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.1

Conclusions

In this study, four AMPs were successfully synthesized with SPPS and MICs
were determined by a refined protocol of my design. The use of iso-sensitest broth
eliminated the need for supplementation for specific bacteria and acted as a universal
growth medium for all 8 bacteria tested in this study. Polypropylene 96-well plates were
used as a test vessel instead of polystyrene, ensuring the surface properties of the test
vessel do not interfere with the MIC assay. Finally, the use of resazurin as a colorimetric
indicator after 24-hour incubation diminished possible human error when interpreting the
results. There were discrepancies between the results recorded here and previously
published MIC data, though this is likely attributed to differences in methods used.
Additional studies comparing the two MIC assays with the peptides could help to confirm
or eliminate these discrepancies.
Identifying RIKA’s activity against K. pneumoniae and E. coli, along with
confirming activity against S. aureus and P. aeruginosa is significant since many
serovars of these organisms are multidrug-resistant ESKAPE pathogens. The antibiotic
resistance crisis continues to be an impending threat to healthcare and steps to develop
novel therapies is essential. Options for treating ESKAPE pathogens are especially
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critical due to their increasing prevalence and pan-resistance. With the lull in the novel
discovery of antibiotic drugs, alternative antibiotic therapies have become more
important than ever before. The consistent outperformance of RIKA over RR suggests
significant antimicrobial activity stemming from the combination of isoleucine, lysine,
and alanine.
IGR and HQ showed no activity in this study. This is not surprising since these
AMPs are related to cathepsin G, a protein that is known to have antimicrobial properties
against oral pathogens and the bacteria tested in this study were not associated with oral
infections.17 Previous publications suggest that IGR and HQ can increase antimicrobial
activity when added to other AMPs. Overall, this project demonstrates my ability to
synthesize peptides using SPPS and to design an assay to overcome 3 major concerns for
conducting MICs with AMPs, providing a more comprehensive evaluation of
antimicrobial activity.
5.2

Future Directions

Given the results reported here there are several directions this project could
develop in the future. Some are related to using these four AMPs and some to modifying
the AMP sequences. Initially, additional MIC assays will help further define the exact
MIC for each peptide followed by MBC assays and Time-kill kinetics assays. This study
used a two-fold dilution series to report MICs for these four AMPs. Using a smaller
dilution factor (i.e. 0.5-fold) would define a more precise MIC for these AMPs. These
precise values will provide a benchmark for research focused on improving the
antimicrobial activity by modifying the AMPs used in this study. Modifications to amino
acid sequences, specifically adding residues, will provide insight on the residues or
domains that provide the most antimicrobial activity.
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Modifications of interest include adding more lysine residues, isoleucine residues,
IGR domains, and HQ domains to RR and RIKA. Previous publications suggested that
isoleucine and lysine are important for antimicrobial activity and found that adding IGR
and HQ to the ends of peptides can improve antimicrobial activity.17,18 Next, combination
therapy studies, which involve testing two or more peptides concurrently, will provide
insight regarding potential synergy. Finally, to demonstrate safety of these AMPs by
evaluating their cytotoxicity with various human cell types. This is one of the necessary
and important steps for any antibiotic moving through the antibiotic pipeline prior to
clinical studies.
Another direction is to continue defining the spectrum of activity of these AMPs.
However, this direction also involves refining the MIC assay protocol by further
modifying methods to account for fastidious bacteria. Oral bacteria Aggregatibacter
actinomycetemcomitans and Streptococcus mutans are two bacteria of interest, as IGR
and HQ previously showed antibiotic activity against them.17 A consideration for these
strains is the required 48-72 incubation periods, while the MIC assay protocol used in this
study is limited to 24-hour incubation.17 Testing additional ESKAPE pathogen species
and clinical isolates of previously tested bacteria will also provide information regarding
the clinically relevant antimicrobial activity of these four AMPs. Testing more ESKAPE
pathogen strains such as Enterococcus faecium, Acintobacter baumanni, and
Enterobacter strains will provide further insight into the activity of these AMPs on the
pathogens posing significant threats to our healthcare system.
Once these studies are completed, applications such as inserting the AMPs into
hydrogels as a wound healing application can be pursued.
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CHAPTER 6
APPENDIX

6.1

Amino Acids Used in this Study

Table 6-1. Amino Acids Used in this Study
Fmoc/Protecting
Amount used
Groups with Amino
in this study (g)
Amino Acids
Acids
0.0957
A Alanine
Fmoc-Ala-OH
0.0914
G Glycine
Fmoc-Gly-OH
0.1906
H Histidine
Fmoc-His(Trt)-OH
0.1087
I
Isoleucine
Fmoc-Ile-OH
0.1441
K Lysine
Fmoc-Lys(Boc)-OH
0.1087
L Leucine
Fmoc-Leu-OH
0.1835
N Asparagine
Fmoc-Asn(trt)-OH
0.1038
P Proline
Fmoc-Pro-OH
0.1878
Q Glutamine
Fmoc-Gln(Trt)-OH
0.1995
R Arginine
Fmoc-Arg(Pbf)-OH
0.1619
W Tryptophan
Fmoc-Trp(Boc)-OH
0.1413
Y Tyrosine
Fmoc-Tyr(tBu)-OH
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Catalog
Number
AFA101
AFG101
AFH105
AFI101
AFK105
AFL101
AFN105
AFP101
AFQ105
AFR105
AFW105
AFY105
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6.2

MIC Assay General Plate Loading Scheme

Figure 6-1. MIC Assay Plate Loading Scheme.
Water is added first and followed by adding the peptides. Serial dilution with only
peptides and water. Serial dilution for antibiotic control. Next, 3.3x iso-sensitest broth is
added to all wells and then AlamarBlue is added to all wells. Finally, bacteria is added to
appropriate wells and all wells are mixed. Pipette tips must be changed for each well
when adding bacteria and mixing the wells.
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6.3
6.3.1

MALDI Results

MALDI-IGR

Figure 6-2. MALDI Results for IGR. IGR sample was acquired in the 500-2000
a range with 20% attenuation and 35% energy. 514.42 is IGR. There is also a strong peak
at 736.42, this is likely Fmoc attached to IGR.
6.3.2

MALDI-HQ

Figure 6-3. MALDI Results for HQ. HQ sample acquired in the 500-3000 Da
range with 20% attenuation and 20% energy. 941.47 is HQ. This is because the C
terminus is CONH2 instead of COOH.
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6.3.3

MALDI-RR

Figure 6-4. MALDI Results for RR. RR sample acquired in 600-4000 Da range
with 20% attenuation and 35% energy. 1553.01 is RR. This is because the C terminus is
CONH2 instead of COOH.
6.3.4

MALDI-RIKA

Figure 6-5. MALDI Results for RIKA. RIKA sample acquired in 500-3000 Da
range with 20% attenuation and 35% energy. 1865.16 is RIKA.
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